CEO Dan Browne insists that Revance Therapeutics Inc.'s technology is the first innovation in neuromodulators in 30 years, providing a longer-lasting botulinum toxin-based injection for aesthetic and therapeutic uses than the four approved products in this category, including Allergan PLC's market-leading blockbuster Botox (onabotulinumtoxinA).
Revance's claim that lead product candidate RT002 (daxibotulinumtoxinA) can beat the three-to-four-month duration of efficacy of existing neurotoxins by two...








